## 2-(2-Methoxyphenyl)-1H-indole: A Promising Molecule in Research
**2-(2-Methoxyphenyl)-1H-indole** is a **heterocyclic organic compound** that has garnered interest in various research fields due to its potential applications in:
**1. Pharmacology:**
* **Antioxidant activity:** Studies show that this molecule possesses antioxidant properties, potentially protecting cells from damage caused by free radicals. This could be beneficial in treating various diseases linked to oxidative stress, like cancer and neurodegenerative disorders.
* **Anti-inflammatory effects:** This indole derivative has exhibited anti-inflammatory properties in research, indicating potential use in managing inflammatory conditions like arthritis or inflammatory bowel disease.
* **Antibacterial activity:** Some research suggests that 2-(2-Methoxyphenyl)-1H-indole might have antibacterial activity against certain bacteria, making it a potential target for developing new antibiotics.
* **Anti-cancer activity:** Preliminary research indicates that this molecule could have anti-cancer effects by inhibiting the growth and proliferation of certain cancer cells. Further investigation is needed to confirm its therapeutic potential in this area.
**2. Materials Science:**
* **Organic semiconductors:** The unique electronic properties of 2-(2-Methoxyphenyl)-1H-indole make it a promising candidate for use in organic semiconductors. These semiconductors can be used in various applications, including solar cells, organic light-emitting diodes (OLEDs), and transistors.
**3. Chemical Synthesis:**
* **Intermediate for other compounds:** This indole derivative serves as a valuable building block in the synthesis of various other biologically active compounds, making it important for drug discovery and development.
**Importance for Research:**
* **Potential for new therapeutic drugs:** The biological activities of 2-(2-Methoxyphenyl)-1H-indole make it a promising lead compound for developing novel medications to treat various diseases.
* **New materials development:** Its unique electronic properties make it an attractive candidate for research in developing new organic materials with potential applications in electronics and optoelectronics.
* **Understanding structure-activity relationships:** Studying the interactions of this molecule with biological systems allows researchers to gain a deeper understanding of the relationship between molecular structure and biological activity, ultimately contributing to the development of new drugs and materials.
**Note:**
While the potential applications of 2-(2-Methoxyphenyl)-1H-indole are promising, it's important to emphasize that much of the research is still in its early stages. Further studies are required to fully understand its mechanism of action, safety, and efficacy before it can be used clinically.
| ID Source | ID |
|---|---|
| PubMed CID | 901191 |
| CHEMBL ID | 1449007 |
| CHEBI ID | 120522 |
| SCHEMBL ID | 5634916 |
| Synonym |
|---|
| smr000114556 |
| MLS000547194 , |
| 2-(1h-indol-2-yl)phenyl methyl ether |
| AI-204/42879112 |
| STK166477 |
| 2-(2-methoxyphenyl)-1h-indole |
| CHEBI:120522 |
| HMS2351F15 |
| AKOS005409296 |
| GYUBKMFGRAIVMZ-UHFFFAOYSA-N |
| 6-methoxyphenylindole |
| 2-(2'-methoxyphenyl)-1h-indole |
| CHEMBL1449007 |
| SCHEMBL5634916 |
| 1h-indole,2-(2-methoxyphenyl)- |
| 40756-71-6 |
| bdbm68671 |
| cid_901191 |
| Q27208375 |
| Class | Description |
|---|---|
| phenylindole | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 79.4328 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 25.1189 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 56.2341 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 15.1014 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 84.2789 | 0.1000 | 20.8793 | 79.4328 | AID588453; AID588456 |
| ClpP | Bacillus subtilis | Potency | 39.8107 | 1.9953 | 22.6730 | 39.8107 | AID651965 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 16.4687 | 0.0041 | 10.8903 | 31.5287 | AID504466; AID504467 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 14.1254 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 35.4813 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| P53 | Homo sapiens (human) | Potency | 70.7946 | 0.0731 | 9.6858 | 31.6228 | AID504706 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 39.8107 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 31.6228 | 0.0018 | 15.6638 | 39.8107 | AID894 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 16.3601 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
| ras-related protein Rab-9A | Homo sapiens (human) | Potency | 3.1623 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 112.2020 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 2.8184 | 0.0079 | 8.2332 | 1,122.0200 | AID2546 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 12.5893 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
| transient receptor potential cation channel subfamily V member 1 | Homo sapiens (human) | Potency | 0.0129 | 0.0912 | 0.0912 | 0.0912 | AID623958 |
| neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 2.5119 | 0.0158 | 12.3113 | 615.5000 | AID1461 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 15.8489 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| TPA: protein transporter TIM10 | Saccharomyces cerevisiae S288C | IC50 (µMol) | 46.9000 | 0.5800 | 26.5476 | 75.8000 | AID493003 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| glycogen synthase kinase-3 beta isoform 1 | Homo sapiens (human) | EC50 (µMol) | 300.0000 | 0.2125 | 22.1562 | 83.9400 | AID434954 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| RNA polymerase II cis-regulatory region sequence-specific DNA binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| DNA binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| double-stranded DNA binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| RNA binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| mRNA 3'-UTR binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| protein binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| lipid binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| identical protein binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| pre-mRNA intronic binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| molecular condensate scaffold activity | TAR DNA-binding protein 43 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| intracellular non-membrane-bounded organelle | TAR DNA-binding protein 43 | Homo sapiens (human) |
| nucleus | TAR DNA-binding protein 43 | Homo sapiens (human) |
| nucleoplasm | TAR DNA-binding protein 43 | Homo sapiens (human) |
| perichromatin fibrils | TAR DNA-binding protein 43 | Homo sapiens (human) |
| mitochondrion | TAR DNA-binding protein 43 | Homo sapiens (human) |
| cytoplasmic stress granule | TAR DNA-binding protein 43 | Homo sapiens (human) |
| nuclear speck | TAR DNA-binding protein 43 | Homo sapiens (human) |
| interchromatin granule | TAR DNA-binding protein 43 | Homo sapiens (human) |
| nucleoplasm | TAR DNA-binding protein 43 | Homo sapiens (human) |
| chromatin | TAR DNA-binding protein 43 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1571459 | Antiproliferative activity against human U87MG cells after 72 hrs by sulforhodamine B assay | 2018 | MedChemComm, Nov-01, Volume: 9, Issue:11 | Towards identifying potent new hits for glioblastoma. |
| AID738621 | Antiproliferative activity against human 1321N1 cells assessed as inhibition of cell growth after 48 hrs by MTS assay | 2013 | Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7 | Preliminary biological evaluation and mechanism of action studies of selected 2-arylindoles against glioblastoma. |
| AID1571462 | Antiproliferative activity against human IN1528 cells after 72 hrs by sulforhodamine B assay | 2018 | MedChemComm, Nov-01, Volume: 9, Issue:11 | Towards identifying potent new hits for glioblastoma. |
| AID738618 | Induction of oxidative stress in human 1321N1 cells assessed as increase in reactive oxygens species generation at 500 uM after 1 hr by H2DCFDA dye based flow cytometry | 2013 | Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7 | Preliminary biological evaluation and mechanism of action studies of selected 2-arylindoles against glioblastoma. |
| AID1571461 | Antiproliferative activity against human IN1472 cells after 72 hrs by sulforhodamine B assay | 2018 | MedChemComm, Nov-01, Volume: 9, Issue:11 | Towards identifying potent new hits for glioblastoma. |
| AID1571460 | Antiproliferative activity against human U251MG cells after 72 hrs by sulforhodamine B assay | 2018 | MedChemComm, Nov-01, Volume: 9, Issue:11 | Towards identifying potent new hits for glioblastoma. |
| AID738617 | Induction of oxidative stress in human U87MG cells assessed as increase in reactive oxygens species generation at 500 uM after 1 hr by H2DCFDA dye based flow cytometry | 2013 | Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7 | Preliminary biological evaluation and mechanism of action studies of selected 2-arylindoles against glioblastoma. |
| AID1571463 | Antiproliferative activity against human IN1760 cells after 72 hrs by sulforhodamine B assay | 2018 | MedChemComm, Nov-01, Volume: 9, Issue:11 | Towards identifying potent new hits for glioblastoma. |
| AID738620 | Antiproliferative activity against human U87MG cells assessed as inhibition of cell growth after 48 hrs by MTS assay | 2013 | Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7 | Preliminary biological evaluation and mechanism of action studies of selected 2-arylindoles against glioblastoma. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.29) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||